# Application of a novel myristoylproteomics approach identifies GLIPR2 as a key pro-ferroptotic substrate in non-small cell lung cancer

**Authors:** Yikun Wang, Susu Guo, Wanxin Guo, Xiaoting Tian, Yayou Miao, Shiyu Qiu, Xiangfei Xue, Yongjie Wang, Jiangtao Cui, Xin Xu, Jiayi Wang, Xiao Zhang

PMC · DOI: 10.1016/j.mtbio.2026.102945 · Materials Today Bio · 2026-02-18

## TL;DR

A new method to study myristoylated proteins reveals GLIPR2's role in promoting ferroptosis in lung cancer cells.

## Contribution

A novel myristoylproteomics workflow identifies GLIPR2 as a key pro-ferroptotic substrate.

## Key findings

- NMT1 and NMT2 expression correlates with ferroptosis sensitivity in NSCLC cells.
- GLIPR2 is a novel myristoylated protein with elevated modification in ferroptosis-sensitive cells.
- GLIPR2's pro-ferroptotic activity depends on its N-myristoylation modification.

## Abstract

Protein myristoylation, catalyzed by N-myristoyltransferases (NMT1 and NMT2), is a key co- and post-translational modification involved in cellular signaling, yet its role in ferroptosis remains poorly defined. Here, we developed a novel myristoylproteomics workflow leveraging click chemistry to comprehensively profile N-myristoylated proteins within NSCLC cells. We found that NMT1 and NMT2 expression positively correlates with ferroptosis sensitivity. Genetic or pharmacological inhibition of NMT attenuated ferroptosis, whereas their overexpression enhanced it. Using our optimized quantitative myristoylproteomics platform, we identified GLIPR2 as a novel myristoylated protein with elevated modification levels in ferroptosis-sensitive cells. Functional studies confirmed that GLIPR2 promotes ferroptosis, and this pro-ferroptotic activity of GLIPR2 requires its N-myristoylation, as a myristoylation-deficient mutant (G2A) failed to restore ferroptosis sensitivity. Our work establishes a robust proteomic methodology for mapping protein myristoylation and uncovers the NMT1/NMT2–GLIPR2 axis as a pivotal regulator of ferroptosis. These findings propose new therapeutic strategies for NSCLC.

Image 1

•Developed and optimized a novel click chemistry-based myristoylproteomics approach for systematic identification of NMT substrates.•Discovered that NMT1/NMT2 expression positively correlates with ferroptosis sensitivity in NSCLC cells.•Screened out GLIPR2 as a new myristoylated protein (higher modification in ferroptosis-sensitive cells) via this technique.•Functional validation showed GLIPR2 exerts pro-ferroptotic effect depending on its myristoylation modification.

Developed and optimized a novel click chemistry-based myristoylproteomics approach for systematic identification of NMT substrates.

Discovered that NMT1/NMT2 expression positively correlates with ferroptosis sensitivity in NSCLC cells.

Screened out GLIPR2 as a new myristoylated protein (higher modification in ferroptosis-sensitive cells) via this technique.

Functional validation showed GLIPR2 exerts pro-ferroptotic effect depending on its myristoylation modification.

## Linked entities

- **Genes:** GLIPR2 (GLI pathogenesis related 2) [NCBI Gene 152007], NMT1 (N-myristoyltransferase 1) [NCBI Gene 4836], NMT2 (N-myristoyltransferase 2) [NCBI Gene 9397]
- **Diseases:** non-small cell lung cancer (MONDO:0005233)

## Full-text entities

- **Genes:** PRKACA (protein kinase cAMP-activated catalytic subunit alpha) [NCBI Gene 5566] {aka CAFD1, PKACA, PPNAD4}, ACSL1 (acyl-CoA synthetase long chain family member 1) [NCBI Gene 2180] {aka ACS1, FACL1, FACL2, LACS, LACS1, LACS2}, FTL (ferritin light chain) [NCBI Gene 2512] {aka FTL1, LFTD, NBIA3}, YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, TOMM20 (translocase of outer mitochondrial membrane 20) [NCBI Gene 9804] {aka MAS20, MOM19, TOM20}, GBA3 (glucosylceramidase beta 3 (gene/pseudogene)) [NCBI Gene 57733] {aka CBG, CBGL1, GLUC, KLRP}, FTH1 (ferritin heavy chain 1) [NCBI Gene 2495] {aka FHC, FTH, FTHL6, HFE5, NBIA9, PIG15}, STK11 (serine/threonine kinase 11) [NCBI Gene 6794] {aka LKB1, PJS, hLKB1}, ACBD6 (acyl-CoA binding domain containing 6) [NCBI Gene 84320] {aka NEDPM}, PDIA4 (protein disulfide isomerase family A member 4) [NCBI Gene 9601] {aka ERP70, ERP72, ERp-72}, SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714] {aka ASV, SRC1, THC6, c-SRC, p60-Src}, FYN (FYN proto-oncogene, Src family tyrosine kinase) [NCBI Gene 2534] {aka SLK, SYN, p59-FYN}, GLIPR2 (GLI pathogenesis related 2) [NCBI Gene 152007] {aka C9orf19, GAPR-1, GAPR1, gliPR 2}, NMT2 (N-myristoyltransferase 2) [NCBI Gene 9397], RFTN1 (raftlin, lipid raft linker 1) [NCBI Gene 23180] {aka MIG2, PIB10, PIG9, RAFTLIN}, ATL1 (atlastin GTPase 1) [NCBI Gene 51062] {aka AD-FSP, ATL-1, FSP1, HSN1D, SPG3, SPG3A}, ITGB3BP (integrin subunit beta 3 binding protein) [NCBI Gene 23421] {aka CENP-R, CENPR, HSU37139, NRIF3, TAP20}, NDUFAF4 (NADH:ubiquinone oxidoreductase complex assembly factor 4) [NCBI Gene 29078] {aka C6orf66, HRPAP20, HSPC125, MC1DN15, My013, bA22L21.1}, GPX4 (glutathione peroxidase 4) [NCBI Gene 2879] {aka GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, COX8A (cytochrome c oxidase subunit 8A) [NCBI Gene 1351] {aka COX, COX8, COX8-2, COX8L, MC4DN15, VIII}, ZDHHC8 (zDHHC palmitoyltransferase 8) [NCBI Gene 29801] {aka DHHC8, ZDHHCL1, ZNF378}, GOLGA2 (golgin A2) [NCBI Gene 2801] {aka DEDHMB, GM130}, LPCAT3 (lysophosphatidylcholine acyltransferase 3) [NCBI Gene 10162] {aka C3F, LPCAT, LPLAT 5, LPLAT12, LPSAT, MBOAT5}, CYB5A (cytochrome b5 type A) [NCBI Gene 1528] {aka CYB5, MCB5, METAG}, KEAP1 (kelch like ECH associated protein 1) [NCBI Gene 9817] {aka INrf2, KLHL19}, TFRC (transferrin receptor) [NCBI Gene 7037] {aka CD71, IMD46, T9, TFR, TFR1, TR}, OGFRL1 (opioid growth factor receptor like 1) [NCBI Gene 79627] {aka dJ331H24.1}, ACSL4 (acyl-CoA synthetase long chain family member 4) [NCBI Gene 2182] {aka ACS4, FACL4, LACS4, MRX63, MRX68, XLID63}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, NMT1 (N-myristoyltransferase 1) [NCBI Gene 4836] {aka HsNMT1, NMT}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, ACTB (actin beta) [NCBI Gene 60] {aka BKRNS, BNS, BRWS1, CSMH, DDS1, PS1TP5BP1}, CHCHD3 (coiled-coil-helix-coiled-coil-helix domain containing 3) [NCBI Gene 54927] {aka MICOS19, MINOS3, Mic19, PPP1R22}
- **Diseases:** LUAD (MESH:D000077192), non-small cell lung cancer (MESH:D002289), pancreatic cancer (MESH:D010190), mitochondrial iron overload (MESH:D019190), Tumor (MESH:D009369), lung cancer (MESH:D008175), ovarian cancer (MESH:D010051), weight loss (MESH:D015431), toxicity (MESH:D064420)
- **Chemicals:** heptanol (MESH:D019850), iron (MESH:D007501), octanol (MESH:D000442), water (MESH:D014867), phospholipids (MESH:D010743), glycine (MESH:D005998), glutamate (MESH:D018698), SDS (MESH:D012967), ACN (MESH:C084683), isopropanol (MESH:D019840), copper (MESH:D003300), biotin (MESH:D001710), acids (MESH:D000143), TCEP (MESH:C080938), blasticidin (MESH:C004500), formic acid (MESH:C030544), methanol (MESH:D000432), Fer-1 (MESH:C573944), methionine (MESH:D008715), IMP-1088 (MESH:C000723047), CoQ10 (MESH:C024989), streptomycin (MESH:D013307), lipid peroxide (MESH:D008054), Tris(2-chloroethyl) phosphate (MESH:C031324), Triton X-100 (MESH:D017830), acetonitrile (MESH:C032159), Azide (MESH:D001386), MDA (MESH:D015104), EDTA (MESH:D004492), agarose (MESH:D012685), Lipid (MESH:D008055), cysteine (MESH:D003545), chloroform (MESH:D002725), CO2 (MESH:D002245), GSH (MESH:D005978), FA (MESH:D005492), ROS (MESH:D017382), alkyne (MESH:D000480), McCoy's 5A medium (MESH:C113109), DMSO (MESH:D004121), membrane lipid (MESH:D008563), Myristic acid (MESH:D019814), PBS (MESH:D007854), PE-AA (MESH:C050457), puromycin (MESH:D011691), erastin (MESH:C477224), penicillin (MESH:D010406), CuSO4 (MESH:D019327), polyunsaturated fatty acids (MESH:D005231), TBTA (MESH:C047985), LysC (-), GSSG (MESH:D019803), NADPH (MESH:D009249)
- **Species:** Mycoplasma (genus) [taxon 2093], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** C1991S, G2A, G) for 24, glycine 2 to alanine
- **Cell lines:** H460 — Homo sapiens (Human), Lung large cell carcinoma, Cancer cell line (CVCL_0459), SK-MES-1 — Homo sapiens (Human), Lung squamous cell carcinoma, Cancer cell line (CVCL_0630), FYN- — Homo sapiens (Human), Chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_SP09), LCLC-103H — Homo sapiens (Human), Lung large cell carcinoma, Cancer cell line (CVCL_1375), Calu-1 — Homo sapiens (Human), Lung squamous cell carcinoma, Cancer cell line (CVCL_0608), OCC1-F — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_H580), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), HEK-293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), NCI-H1793 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_1496), EBC-1 — Homo sapiens (Human), Neuroblastoma, Cancer cell line (CVCL_E218), A-427 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_1055), HCC4006 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_1269), NMT1/2 — Rattus norvegicus (Rat), Rat yolk sac carcinoma, Cancer cell line (CVCL_VI69), NCI-H226 — Homo sapiens (Human), Pleural epithelioid mesothelioma, Cancer cell line (CVCL_1544), ABC-1 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_1066), BALB/c — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0184), PC-9 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_B260)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12955691/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12955691/full.md

## References

55 references — full list in the complete paper: https://tomesphere.com/paper/PMC12955691/full.md

---
Source: https://tomesphere.com/paper/PMC12955691